Publication Name	World Journal of Diabetes
Manuscript ID	16262
Country	United Kingdom

Received	2015-01-07 08:37
Peer-Review Started	2015-01-08 20:14
To Make the First Decision	2015-03-06 10:32
Return for Revision	2015-03-11 11:18
Revised	2015-03-14 16:06
Second Decision	2015-04-10 18:19
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-04-20 14:42
Articles in Press	2015-04-20 14:42
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-06-10 09:53
Publish the Manuscript Online	2015-06-20 17:24

ISSN	1948-9358 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, General & Internal
Manuscript Type	Editorial
Article Title	Incretin manipulation in diabetes management
Manuscript Source	Invited Manuscript
All Author List	Joseph M Pappachan, AV Raveendran and Rajagopalan Sriraman
Funding Agency and Grant Number
Corresponding Author	Dr. Joseph M Pappachan, MD, MRCP (London), Department of Endocrinology and Diabetes, New Cross Hospital, the Royal Wolverhampton Hospital NHS Trust, Wolverhampton Road, WV10 0QP Wolverhampton, United Kingdom. drpappachan@yahoo.co.in
Key Words	Incretin hormones; Incretin-based therapies; Glucagon-like peptide-1 analogues; Dipeptidyl peptidase-4 inhibitors; Pancreatitis
Core Tip	Development of multiple pharmaceutical agents by the manipulation of incretin hormone system provided the global scientific fraternity several drugs for the management of type 2 diabetes mellitus (T2DM) in recent years. These agents, the glucagon-like peptide-1 analogues and dipeptidyl peptidase-4 inhibitors, form the incretin-based therapies that be?nefited T2DM patients with significant reduction of hemoglobin A1c, low risk of hypoglycemia, favorable effects on management of overweight and obesity, and enhanced efficacy in combination regimens for glycemic management with other anti-diabetics. Two recent meta-analyses discarded the concern about elevated pancreatitis risk. The article discusses the incretin-based therapies for the management of T2DM.
Publish Date	2015-06-20 17:24
Citation	Pappachan JM, Raveendran AV, Sriraman R. Incretin manipulation in diabetes management. World J Diabetes 2015; 6(6): 774-781
URL	http://www.wjgnet.com/1948-9358/full/v6/i6/774.htm
DOI	http://dx.doi.org/10.4239/wjd.v6.i6.774

Full Article (PDF)	WJD-6-774.pdf
Full Article (Word)	WJD-6-774.doc
Manuscript File	16262-Review.doc
Answering Reviewers	16262-Answering reviewers.pdf
Audio Core Tip	16262-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	16262-Conflict-of-interest statement.pdf
Copyright License Agreement	16262-Copyright assignment.pdf
Peer-review Report	16262-Peer-review(s).pdf
Scientific Misconduct Check	16262-Scientific misconduct check.pdf
Scientific Editor Work List	16262-Scientific editor work list.pdf